References
Athanasuleas CL, Stanley AW, Jr., Buckberg GD, Dor V, DiDonato M, Blackstone EH (2001) Surgical anterior ventricular endocardial restoration (SAVER) in the dilated remodeled ventricle after anterior myocardial infarction. RESTORE group. Reconstructive Endoventricular Surgery, returning Torsion Original Radius Elliptical Shape to the LV. J Am Coll Cardiol 37:1199–1209
Bansch D, Antz M, Boczor S, Volkmer M, Tebbenjohanns J, Seidl K, Block M, Gietzen F, Berger J, Kuck KH (2002) Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 105:1453–1458
Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352:225–237
BEST Investigatiors (2001) A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344:1659–1667
Bouvy ML, Heerdink ER, Leufkens HG, Hoes AW (2003) Predicting mortality in patients with heart failure: a pragmatic approach. Heart 89:605–609
Bradley DJ, Bradley EA, Baughman KL, Berger RD, Calkins H, Goodman SN, Kass DA, Powe NR (2003) Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA 289:730–740
Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM (2004) Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350:2140–2150
CIBIS-II Investigators (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353:9–13
Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Brighetti G, Marino P, Zardini P (2002) Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 40:304–310
Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352:1539–1549
Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, van Gilst WH, Widimsky J, Freemantle N, Eastaugh J, Mason J (2003) The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 24:442–463
Cleland JGF, Erhardt L, Murry G, Hall AS, Ball SG, on, behalf, of, the, AIRE, Study, Investigators (1997) Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. Eur Heart J 18:41–51
Cohn J, Johnson G, Ziesche S, Cobb FR, Francis GS, Tristani FE, Smith R, Dunkman WB, Loeb HS, Wong M, Bhat G, Golgman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C (1991) A comparison of enalapril with hydralazine-isosorbide dinitrate in treatment of chronic congestive heart failure: V-HeFT II. N Engl J Med 325:303–310
Cohn JN, Archibald GD, Ziesche S, Franciosy JA, Harston WE, Tristani FE, Dunkman B, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B (1986) Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 314:1547–1552
Cohn JN, Ferrari R, Sharpe N (2000) Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 35:569–582
Cohn JN, Tognoni G (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667–1675
Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, Cintron G, Boden W, Baruch L, Rochin P, Loss L (1997) Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure. Circulation 96:856–863
CONSENSUS Trail Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316:1429–1435
Cosin J, Diez J (2002) Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 4:507–513
de Lemos JA, McGuire DK, Drazner MH (2003) B-type natriuretic peptide in cardiovascular disease. Lancet 362:316–322
Dickstein K, Kjekshus J (2002) Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360:752–760
Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336:525–533
Erbel R, Neumann T, Zeidan Z, Bartel T, Buck T (2002) Echokardiographische Diagnostik der diastolischen Herzinsuffizienz. Herz 27:99–106
Erdmann E (2003) Kalziumantagonisten. In: Erdmann E (Hrsg) Herzinsuffizienz, 3. Aufl. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, S 338–342
Erdmann E, Lechat P, Verkenne P, Wiemann H (2001) Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 3:469–479
Exner DV, Dries DL, Waclawiw MA, Shelton B, Domanski MJ (1999) Betaadrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 33:916–923
Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Bohm M, Anker SD, Thompson SG, Poole-Wilson PA (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26:215–225
Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, Braunwald E (2000) Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355:1575–1581
Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen LA (2002) Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360:196–202
Gandhi SK, Powers JC, Nomeir AM, Fowle K, Kitzman DW, Rankin KM, Little WC (2001) The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 344:17–22
Gehlbach BK, Geppert E (2004) The pulmonary manifestations of left heart failure. Chest 125:669–682
Gheorghiade M, Gattis WA, Klein L (2003) OPTIME in CHF trial: rethinking the use of inotropes in the management of worsening chronic heart failure resulting in hospitalization. Eur J Heart Fail 5:9–12
Gosselink AT, Crijns HJ, Van Gelder IC, Hillige H, Wiesfeld AC, Lie KI (1992) Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 267:3289–3293
Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362:772–776
Gummert JF, Rahmel A, Bucerius J, Onnasch J, Doll N, Walther T, Falk V, Mohr FW (2003) Mitral valve repair in patients with end stage cardiomyopathy: who benefits? Eur J Cardiothorac Surg 23:1017–1022 (discussion 1022)
Gustafsson F, Torp-Pedersen C, Brendorp B, Seibaek M, Burchardt H, Kober L (2003) Long-term survival in patients hospitalized with congestive heart failure: relation to preserved and reduced left ventricular systolic function. Eur Heart J 24:863–870
Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vitovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, Janosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P (2000) Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 283:1295–1302
Hogg K, Swedberg K, McMurray J (2004) Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 43:317–327
Hoppe UC, Erdmann E (1998) Leitlinien zur Therapie der chronischen Herzinsuffizienz. Im Auftrag der Deutschen Gesellschaft für Kardiologie. Z Kardiol 87:645–658
Hoppe UC, Erdmann E (2001) Leitlinien zur Therapie der chronischen Herzinsuffizienz. Im Auftrag der Deutschen Gesellschaft für Kardiologie. Z Kardiol 90:218–237
Hunt HA, Baker DW, Chin MH, Cinquegrani MP, Feldmanmd AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Jacobs AK, Hiratzka LF, Russell RO, Smith SC Jr (2001) ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult. Circulation 104:2996–3007
Innes CA, Wagstaff AJ (2003) Levosimendan: a review of its use in the management of acute decompensated heart failure. Drugs 63:2651–2671
Jong P, Demers C, McKelvie RS, Liu PP (2002) Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol 39:463–470
Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI (2003) Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 361:1843–1848
Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, Calkins H, Hoch D, Goldberger J, Shalaby A, Sanders WE, Schaechter A, Levine JH (2004) Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350:2151–2158
Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC (1995) A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 333:1670–1676
Krum H, Roecker EB, Mohacsi P, Rouleau JL, Tendera M, Coats AJ, Katus HA, Fowler MB, Packer M (2003) Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. Jama 289:712–718
Lamas GA, Lee KL, Sweeney MO, Silverman R, Leon A, Yee R, Marinchak RA, Flaker G, Schron E, Orav EJ, Hellkamp AS, Greer S, McAnulty J, Ellenbogen K, Ehlert F, Freedman RA, Estes NA, 3rd, Greenspon A, Goldman L (2002) Ventricular pacing or dual-chamber pacing for sinusnode dysfunction. N Engl J Med 346:1854–1862
Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP (1998) Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 98:1184–1191
Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN (2002) Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 40:1414–1421
Massie BM, Shah NB (1996) The heart failure epidemic: magnitude of the problem and potential mitigating approaches. Current Opinion Cardiol 11:221–226
McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-convertingenzyme inhibitors: the CHARM-Added trial. Lancet 362:767–771
McMurray JJ, Stewart S (2000) Epidemiology, aetiology, and prognosis of heart failure. Heart 83:596–602
MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001–2007
Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML (2002) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346:877–883
Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P, Pfisterer M, Perruchoud AP (2004) Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 350:647–654
Murray MD, Deer MM, Ferguson JA, Dexter PR, Bennett SJ, Perkins SM, Smith FE, Lane KA, Adams LD, Tierney WM, Brater DC (2001) Open-label randomized trial of torasemide compared with furosemide therapy for patients with heart failure. Am J Med 111:513–520
Nava S, Larovere MT, Fanfulla F, Navalesi P, Delmastro M, Mortara A (2003) Orthopnea and inspiratory effort in chronic heart failure patients. Respir Med 97:647–653
Packer M (2003) Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure? Circulation 108:2950–2953
Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334:1349–1355
Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF (1999) Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 100:2312–2318
Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC et al (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327:669–677
Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349:1893–1906
Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial–the Losartan Heart Failure Survival Study ELITE II. Lancet 355:1582–1587
Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309–1321
Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene AM (2003) Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362:7–13
Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS (2003) Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. Jama 289:2534–2544
Ramires FJ, Mansur A, Coelho O, Maranhao M, Gruppi CJ, Mady C, Ramires JA (2000) Effect of Spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 85:1207–1211
Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM (2003) Association of serum digoxin concentration and outcomes in patients with heart failure. Jama 289:871–878
Rathore SS, Wang Y, Krumholz HM (2002) Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 347:1403–1411
Registry of the International Society for Heart and Lung Transplantation (1992) Ninth official report 1992. J Heart Lung Transplant 11:599–606
Rihal CS, Davis KB, Kennedy JW, Gersh BJ (1995) The utility of clinical, electrocardiographic, and roentgenographic variables in the prediction of left ventricular function. Am J Cardiol 75:220–223
Rodeheffer RJ (2004) Measuring plasma B-type natriuretic peptide in heart failure: good to go in 2004? J Am Coll Cardiol 44:740–749
Romano MA, Bolling SF (2003) Mitral valve repair as an alternative treatment for heart failure patients. Heart Fail Monit 4:7–12
Senni M, Redfield MM (2001) Heart failure with preserved systolic function. A different natural history? J Am Coll Cardiol 38:1277–1282
Sheldon R, Connolly S, Krahn A, Roberts R, Gent M, Gardner M (2000) Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy: the Canadian Implantable Defibrillator Study. Circulation 101:1660–1664
Sin DD, Man SF (2003) Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 107:1514–1519
Singh SN, Flechter RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling C, Lazzeri D (1995) Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 333:77–82
Sirak TE, Jelic S, Le Jemtel TH (2004) Therapeutic update: non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 44:497–502
SOLVD Investigators (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 327:685–691
SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293–302
Strickberger SA, Hummel JD, Bartlett TG, Frumin HI, Schuger CD, Beau SL, Bitar C, Morady F (2003) Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia–AMIOVIRT. J Am Coll Cardiol 41:1707–1712
Sweeney MO, Hellkamp AS, Ellenbogen KA, Greenspon AJ, Freedman RA, Lee KL, Lamas GA (2003) Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation 107:2932–2937
Taylor AL, Ziesche S, Yancy C, Carson P, D’Agostino R Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN (2004) Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351:2049–2057
Teerlink JR, Jalaluddin M, Anderson S, Kukin ML, Eichhorn EJ, Francis G, Packer M, Massie BM (2000) Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators. Circulation 101:40–46
Teo KK, Yusuf S, Pfeffer M, Torp-Pedersen C, Kober L, Hall A, Pogue J, Latini R, Collins R (2002) Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 360:1037–1043
The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators (1997) A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 337:1576–1583
Trappe HJ (2003) Leitlinien der Deutschen Gesellschaft für Kardiologie—Herz- und Kreislaufforschung. Z Kardiol 92:689–693
WHO (1995) Physician Guidelines (for GPs) designed to be translated and distributed worldwide to primary care physicians
Working, Group, on, Cardiac, Rehabilitation, and, Exercise, Physiology (2001) Recommendations for exercise training in chronic heart failure patients. Eur Heart J 22:125–135
Working, Group, Report (1998) How to diagnose diastolic heart failure. European Study Group on Diastolic Heart Failure. Eur Heart J 19:990–1003
Wright (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981–2997
Wuttke H, Rau T, Eschenhagen T (2004) Genpolymorphismen in Arzneimittelabbauenden Enzymen. Dtsch Med Wochenschr 129:831–835
Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362:777–781
Zile MR, Gaasch WH, Carroll JD, Feldman MD, Aurigemma GP, Schaer GL, Ghali JK, Liebson PR (2001) Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation 104:779–782
Author information
Authors and Affiliations
Additional information
in Zusammenarbeit mit der Arzneimittelkommission der Deutschen Ärzteschaft
Herausgegeben vom Vorstand der Deutschen Gesellschaft für Kardiologie—Herz- und Kreislaufforschung e.V. Bearbeitet im Auftrag der Kommission für Klinische Kardiologie R. H. Strasser, D. Andresen, F. de Haan, G. Ertl, H. Mudra, A. Osterspey, H. J. Trappe, K. Werdan, außerdem G. Arnold, H. M. Hoffmeister, E. Fleck
Diese Leitlinie ist eine wissenschaftlich und systematisch erarbeitete Stellungnahme der Deutschen Gesellschaft für Kardiologie—Herz- und Kreislaufforschung e.V. (DGK), die den gegenwärtigen Erkenntnisstand zum Thema wiedergibt und allen behandelnden Ärzten und ihren Patienten die Entscheidungsfindung für eine angemessene Behandlung dieser spezifischen Krankheitssituation erleichtern soll. Diese Leitlinie ersetzt nicht die ärztliche Evaluation des individuellen Patienten und die Anpassung der Diagnostik und Therapie an die spezifische Situation des einzelnen Patienten.
Empfehlungsgrad Definition
I. Evidenz oder allgemeine Übereinkunft, dass eine Therapieform oder eine diagnostische Maßnahme effektiv, nützlich oder heilsam ist.
II. Widersprüchliche Evidenz und/oder unterschiedliche Meinungen über den Nutzen/die Effektivität einer Therapieform oder einer diagnostischen Maßnahme.
IIa. Evidenzen/Meinungen favorisieren den Nutzen bzw. die Effektivität einer Maßnahme.
IIb. Nutzen/Effektivität einer Maßnahme ist weniger gut durch Evidenzen/Meinungen belegt.
Evidenzniveau Definition
A. Die Empfehlung wird mindestens durch zwei randomisierte Studien gestützt.
B. Die Empfehlung wird durch eine randomisierte Studie und/oder eine Metaanalyse nicht-randomisierter Studien gestützt.
C. Konsensus-Meinung von Experten, basierend auf Studien und klinischer Erfahrung.
Rights and permissions
About this article
Cite this article
Hoppe, U.C., Böhm, M., Dietz, R. et al. Leitlinien zur Therapie der chronischen Herzinsuffizienz. ZS Kardiologie 94, 488–509 (2005). https://doi.org/10.1007/s00392-005-0268-4
Issue Date:
DOI: https://doi.org/10.1007/s00392-005-0268-4